Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
暂无分享,去创建一个
R. Arceci | P. Steinherz | P. Gaynon | S. Jeha | J. Franklin | S. Goldman | S. Rheingold | S. Weitman | B. Razzouk | R. Kadota | L. Bomgaars | L. Steinherz | M. Rytting | L. Luchtman-Jones | E. Albano | A. Altman | K. Ritchey | V. Shen | T. Griffin | B. Gordon | Edythe A. Albano
[1] P. Steinherz,et al. A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia. , 2007 .
[2] M. McDevitt,et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. , 2007, Blood.
[3] P. Steinherz,et al. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. , 2007, Journal of pediatric hematology/oncology.
[4] G. Gustafsson,et al. Improved outcome after relapse in children with acute myeloid leukaemia , 2007, British journal of haematology.
[5] C. Pui,et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.
[6] J. Fay,et al. Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity. , 2006 .
[7] Z. Estrov,et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. , 2006, Blood.
[8] J. Kurtzberg,et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Pui,et al. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia , 2005, Pediatric blood & cancer.
[10] V. Gandhi,et al. Biochemical modulation of cytarabine triphosphate by clofarabine , 2005, Cancer Chemotherapy and Pharmacology.
[11] P. Bonate,et al. Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia , 2004, Journal of clinical pharmacology.
[12] R. Arceci,et al. The changing face of clinical trials , 2004, Pediatric blood & cancer.
[13] J. Abrahamsson,et al. The paediatric cytarabine syndrome can be viewed as a drug‐induced cytokine release syndrome , 2004, British journal of haematology.
[14] H. Kantarjian,et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. , 2004, Blood.
[15] C. Harrison,et al. MRC trials in childhood acute myeloid leukaemia. , 2004, Annals of hematology.
[16] A. Baruchel,et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Veys,et al. Long‐term follow‐up of relapsed childhood acute lymphoblastic leukaemia , 2003, British journal of haematology.
[18] P. Steinherz,et al. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia , 2003, Leukemia.
[19] H. Kantarjian,et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.
[20] R. Arceci,et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Hirschfeld,et al. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Khuri,et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Eriksson,et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. , 2003, Biochemical pharmacology.
[24] Y. Ravindranath. Recent advances in pediatric acute lymphoblastic and myeloid leukemia , 2003, Current opinion in oncology.
[25] V. Kataja,et al. Systemic Capillary Leak Syndrome Resulting from Gemcitabine Treatment in Renal Cell Carcinoma: A Case Report , 2003, Journal of chemotherapy.
[26] R. Arceci. Progress and controversies in the treatment of pediatric acute myelogenous leukemia , 2002, Current opinion in hematology.
[27] M. Jarfelt,et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. , 2001, Medical and pediatric oncology.
[28] L. Spaggiari,et al. Gemcitabine-induced systemic capillary leak syndrome. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] W. Plunkett,et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] W. Plunkett,et al. Purine and pyrimidine nucleoside analogs. , 2001, Cancer chemotherapy and biological response modifiers.
[31] J. Montgomery,et al. Preclinical Antitumor Activity of 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (C1-F-Ara-A) , 2000, Nucleosides, nucleotides & nucleic acids.
[32] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[33] A. Oakhill,et al. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. , 1999, Medical and pediatric oncology.
[34] L. Hertel,et al. Comparison of the Mechanism of Cytotoxicity of 2-Chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine, 2-Chloro-9-(2-deoxy-2-fluoro-β-d-ribofuranosyl)adenine, and 2-Chloro-9-(2-deoxy-2,2-difluoro-β-d-ribofuranosyl)adenine in CEM Cells , 1999 .
[35] K. Wheatley,et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial , 1999, Leukemia.
[36] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[37] J. Boos,et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia , 1998, Leukemia.
[38] S. Feig,et al. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. , 1998, Medical and pediatric oncology.
[39] J. Kersey,et al. Fifty years of studies of the biology and therapy of childhood leukemia. , 1997, Blood.
[40] R. Gray,et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. , 1998, British journal of haematology.
[41] N. Pavlakis,et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine , 1997, Cancer.
[42] J. Shuster,et al. Pediatric Phase II Cancer Chemotherapy Trials: A Pediatric Oncology Group Study , 1997, Journal of pediatric hematology/oncology.
[43] Malcolm A. Smith,et al. Pediatric Phase I Drug Tolerance: A Review and Comparison of Recent Adult and Pediatric Phase I Trials , 1996, Journal of pediatric hematology/oncology.
[44] S. Richards,et al. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. , 1996, Archives of disease in childhood.
[45] B. Cheson,et al. Neurotoxicity of purine analogs: a review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Smith,et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Blood.
[47] T. Kipps,et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[48] R Hartmann,et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. , 1991, Blood.
[49] M. Schell,et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Longo,et al. Cancer chemotherapy and biological response modifiers annual , 1987 .